Hilo (previously known as Aktiia), a blood pressure intelligence platform, announced an oversubscribed $42 million (over CHF 34 million) Series B funding round, co-led by Earlybird Health and Wellington Partners, with new investors Kfund and naturalX Health Ventures, and participation from existing investors redalpine, Khosla Ventures, Molten Ventures, Translink Capital, and Verve Ventures. The funding, which has brought the total financing above $100 million, will accelerate the company’s mission to manage the world’s blood pressure.
The transition to Hilo marks a significant milestone in the company’s journey. It aligns with its vision of healthier blood pressure for all while continuing to deliver the trusted technology and reports central to its platform.
This latest funding builds on a period of major momentum for the company during which it has achieved several major milestones, including securing CE marking for its innovative mobile phone camera blood pressure monitoring technology, securing regulatory approvals in Canada, Australia and Saudi Arabia, achieving 76% compounded annual revenue growth, and completing a pivotal clinical trial ahead of its U.S. FDA application submission.
Along with this funding, Aktiia is introducing its new brand identity: Hilo – a rebrand which reflects the company’s global ambition to make cuffless, clinically validated blood pressure monitoring universally accessible and effortless. The transition to Hilo marks an essential milestone in the company’s journey, aligning with its vision of healthier blood pressure for all, while continuing to deliver the trusted technology and reports central to its platform.
With over 120,000 devices sold, Hilo has already established itself as a standout in the health tech space. The company has developed a foundation Machine Learning model specifically designed for blood pressure. This model has been trained on tens of billions of optical signals from real-world users and further refined with hundreds of millions of calibration points, strengthening its position as the leader in the emerging cuffless blood pressure monitoring (CBPM) category.
What the funding will be used for: This Series B funding will advance continued product innovation, expansion into new markets, and the development of its blood pressure intelligence platform to support enterprise use cases.
KEY QUOTES:
“This funding round is a testament to the confidence our investors have in Hilo’s groundbreaking technology and our mission to manage the world’s blood pressure via more frequent, convenient and accurate measurements. With billions worldwide suffering from hypertension, only 20% of whom are in control of their blood pressure, the need for innovative, accessible blood pressure monitoring solutions has never been greater. Our rebrand to Hilo represents more than just a name change, it’s a commitment to empowering users around the world with smarter tools to optimise their health. We are grateful to early Aktiia customers for their support and to our investors, new and existing, for their faith.”
Raghav “Rags” Gupta, CEO of Hilo
“Hilo stands at the intersection of medical-grade precision and consumer-centric accessibility. By building on a validated medical device platform and an intuitive, user-friendly design, they bridge the gap between clinical reliability and everyday usability. It’s a rare combination that empowers users to take meaningful control of their health with minimal effort. This is especially critical given the enormous medical need: uncontrolled high blood pressure remains one of the leading risk factors for death worldwide.”
Christoph Massner, Principal at Earlybird Health, who will join Hilo’s Board of Directors
“We are excited to co-lead this financing and to be backing Hilo’s innovative technology, which provides groundbreaking advancements to the billions of people with elevated blood pressure today. We believe that real-time and continuous access to blood pressure information will change the way we think about the monitoring and management of one of the most common risk factors to human health.”
Johannes Fischer, Managing Partner at Wellington Partners
